FDA Approval For AstraZeneca - Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer

  • The FDA has approved AstraZeneca plc AZN and Daiichi Sankyo's DSKYF Enhertu (trastuzumab deruxtecan) for adult patients with unresectable or metastatic HER2-positive breast cancer.
  • The approval covers patients who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of therapy.
  • Also Read: Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer.
  • The approval was based on positive results from the DESTINY-Breast03 Phase 3 trial that showed Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine.
  • Regulatory applications for Enhertu are currently under review in Europe, Japan, and several other countries for unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen based on the results from the DESTINY-Breast03 trial.
  • Price Action: AZN shares are down 3.28% at $64.56 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!